文献速递妇科

手术方式对宫颈癌根治性子宫切除术患者肿瘤学结局的影响

Impact of surgical approach on oncologic outcomes in women undergoing radical hysterectomy for cervical cancer.
PubMed 文献 · Am J Obstet Gynecol · 2019-07-06

加拿大安大略省2006至2017年基于人群的回顾性队列研究,纳入958例接受根治性子宫切除术的宫颈癌患者,比较微创与开腹手术的肿瘤学结局并校正外科医生手术量。校正后,IB期患者微创手术与死亡风险(HR 2.20;95%CI 1.15-4.19)和复发风险(HR 1.97;95%CI 1.10-3.50)升高相关,IA期无显著差异。作者认为IB期宫颈癌应推荐开腹根治性子宫切除术。

要点

  • IB期宫颈癌微创根治性子宫切除术校正外科医生手术量后仍与死亡和复发风险升高相关。
  • IA期患者微创与开腹手术的死亡和复发风险无显著差异。
  • 作者认为IB期宫颈癌应推荐开腹根治性子宫切除术,早期微小病变亚组可能仍安全但需进一步研究。

核心结论

  • 校正外科医生手术量后,IB期宫颈癌患者微创根治性子宫切除术仍与死亡和复发风险升高相关,开腹根治性子宫切除术应作为该人群的推荐术式。
  • 对于显微镜下早期病变的亚组患者,微创根治性子宫切除术可能仍安全,但需进一步研究。

研究设计与样本

  • 加拿大安大略省2006至2017年基于人群的回顾性队列研究,纳入由妇科肿瘤医生实施初次根治性子宫切除术的宫颈癌患者958例(微创475例,开腹483例),平均年龄45.9岁,中位随访6年。
  • 采用多变量边际Cox比例风险模型和病因特异性风险模型评估手术方式与全因死亡及复发的关联,并按外科医生层面聚类,检验手术方式与病理分期或外科医生手术量的交互作用。

主要发现

  • 微创手术中89.6%为腹腔镜,10.4%为机器人。
  • 未校正的5年累积发生率:IB期患者全因死亡微创12.5% vs 开腹5.4%,宫颈癌死亡微创9.3% vs 开腹3.3%,复发微创16.2% vs 开腹8.4%,微创均显著升高;但 전체队列整体未显著升高。
  • 校正患者因素和外科医生手术量后,IB期患者(n=534)微创根治性子宫切除术与开腹相比死亡风险升高(HR 2.20;95%CI 1.15-4.19),复发风险升高(HR 1.97;95%CI 1.10-3.50)。
  • IA期患者(n=244)微创与开腹相比死亡风险(HR 0.73;95%CI 0.13-4.01)和复发风险(HR 0.34;95%CI 0.10-1.10)无显著差异。

临床怎么用

  • 作者认为,IB期宫颈癌患者应推荐开腹根治性子宫切除术。
  • 作者指出,显微镜下早期病变的亚组患者中微创根治性子宫切除术可能仍安全,但需进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies demonstrating shorter survival among cervical cancer patients undergoing minimally invasive versus open radical hysterectomy could not account for surgeon volume and require confirmation in other jurisdictions with larger sample sizes, longer follow-up, and data on disease recurrence. OBJECTIVE: To determine if surgical approach is associated with oncologic outcomes in cervical cancer patients undergoing minimally invasive or open radical hysterectomy, while accounting for mechanistic factors including surgeon volume. STUDY DESIGN: We performed a population-based retrospective cohort study of cervical cancer patients undergoing primary radical hysterectomy by a gynecologic oncologist from 2006 to 2017 in Ontario, Canada. A multivariable marginal Cox proportional hazards model and cause-specific hazards model were used to evaluate the association of surgical approach with all-cause death and recurrence respectively, clustering at the surgeon level. We tested for interactions between surgical approach and either pathologic stage or surgeon volume. RESULTS: We identified 958 patients (minimally invasive 475; open 483) with mean age 45.9 and a median follow-up of 6 years. Of minimally invasive procedures, 89.6% were performed laparoscopically and 10.4% robotically. The unadjusted 5-year cumulative incidences of all-cause death (minimally invasive 12.5%; open 5.4%), cervical cancer death (minimally invasive 9.3%; open 3.3%), and recurrence (minimally invasive 16.2%; open 8.4%) were significantly increased for minimally invasive radical hysterectomy in patients with stage IB disease, but not the cohort overall. After adjusting for patient factors and surgeon volume, minimally invasive radical hysterectomy was associated with increased rates of death (hazard ratio [HR], 2.20; 95% confidence interval [CI], 1.15-4.19) and recurrence (HR, 1.97; 95% CI, 1.10-3.50) compared to open radical hysterectomy in patients with stage IB disease (n = 534), but not IA disease (n = 244; HR, 0.73; 95% CI, 0.13-4.01; HR, 0.34; 95% CI, 0.10-1.10). CONCLUSION: Minimally invasive radical hysterectomy is associated with increased rates of death and recurrence in patients with stage IB cervical cancer even after controlling for surgeon volume; open radical hysterectomy should be the recommended approach in this population. Although there may be a subset of patients with microscopic early-stage disease for whom minimally invasive radical hysterectomy remains safe, additional studies are required.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Cusimano MC, Baxter NN, Gien LT, et al. Impact of surgical approach on oncologic outcomes in women undergoing radical hysterectomy for cervical cancer. Am J Obstet Gynecol. 2019. PMID: 31288006. doi:10.1016/j.ajog.2019.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。